The company states: “Recursion will present preliminary data during the 2025 Digestive Disease Week meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary activity of REC-4881 for the treatment of familial adenomatous polyposis (FAP). The data will be presented as a late-breaking oral presentation during the Research Forum session on Hereditary GI cancer syndromes on Sunday, May 4, 2025 in San Diego. Currently, there are no FDA-approved therapies for FAP, a rare hereditary autosomal dominant colorectal cancer predisposition syndrome, affecting approximately 50,000 people in the US, France, Germany, Italy, Spain, and the UK. REC-4881 has been granted Fast Track and Orphan Drug designation by the U.S. Food and Drug Administration as well as Orphan Drug designation by the European Commission.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- BTIG Analyst Sees Tempus AI (TEM) as “Significant Free Call Option” with 48% Upside
- Recursion and HealthVerity announce agreement
- Largest borrow rate increases among liquid names
- Cathie Wood’s ARK Investment buys 460K shares of Recursion Pharmaceuticals today
- Biotech Alert: Searches spiking for these stocks today